Literature DB >> 11479511

Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass.

C Joffs1, C A Walker, J W Hendrick, D J Fary, D K Almany, J N Davis, A T Goldberg, F A Crawford, F G Spinale.   

Abstract

BACKGROUND: The bioactive peptide endothelin-1 is elevated during and after cardiopulmonary bypass and exerts cardiovascular effects through its 2 receptor subtypes, endothelin-1A and endothelin-1B. Increased endothelin-1A receptor stimulation after cardiopulmonary bypass can cause increased pulmonary vascular resistance and modulate myocardial contractility. However, whether and to what degree selective endothelin-1A blockade influences these parameters in the postbypass setting is not completely understood.
OBJECTIVES: Our objective was to measure left ventricular function and hemodynamics in a porcine model of cardiopulmonary bypass after selective blockade of endothelin-1A.
METHODS: Adult pigs (n = 23) underwent 90 minutes of cardiopulmonary bypass and were randomized 30 minutes after bypass to receive a selective endothelin-1A antagonist (TBC 11251, 10 mg/kg; n = 13) or saline vehicle (n = 10).
RESULTS: After bypass and before randomization, pulmonary vascular resistance rose nearly 4-fold, and left ventricular preload recruitable stroke work fell to one third of baseline values (both P <.05). In the vehicle group pulmonary vascular resistance continued to rise, and preload recruitable stroke work remained reduced. However, after endothelin-1A blockade, the rise in pulmonary vascular resistance was significantly blunted compared with that in the vehicle group. Moreover, the reduction in pulmonary vascular resistance with endothelin-1A blockade was achieved without a significant change in systemic perfusion pressures.
CONCLUSIONS: The present study demonstrated that increased activity of the endothelin-1A receptor likely contributes to alterations in pulmonary vascular resistance in the postbypass setting. Selective endothelin-1A blockade may provide a means to selectively decrease pulmonary vascular resistance without significant effects on systemic hemodynamics.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11479511     DOI: 10.1067/mtc.2001.114938

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Endothelin-A receptor inhibition after cardiopulmonary bypass: cytokines and receptor activation.

Authors:  Rachael L Ford; Ira M Mains; Ebony J Hilton; Scott T Reeves; Robert E Stroud; Fred A Crawford; John S Ikonomidis; Francis G Spinale
Journal:  Ann Thorac Surg       Date:  2008-11       Impact factor: 4.330

2.  Selective endothelin-1 receptor type A inhibition in subjects undergoing cardiac surgery with preexisting left ventricular dysfunction: Influence on early postoperative hemodynamics.

Authors:  John M Toole; John S Ikonomidis; Wilson Y Szeto; James L Zellner; John Mulcahy; Rachael L Deardorff; Francis G Spinale
Journal:  J Thorac Cardiovasc Surg       Date:  2010-01-13       Impact factor: 5.209

3.  Right ventricular function declines after cardiac surgery in adult patients with congenital heart disease.

Authors:  Mark J Schuuring; Pauline P M Bolmers; Barbara J M Mulder; Rianne A C M de Bruin-Bon; Dave R Koolbergen; Mark G Hazekamp; Wim K Lagrand; Stefan G De Hert; E M F H de Beaumont; Berto J Bouma
Journal:  Int J Cardiovasc Imaging       Date:  2011-06-03       Impact factor: 2.357

4.  Advanced therapy for pulmonary arterial hypertension due to congenital heart disease: a clinical perspective in a new therapeutic era.

Authors:  M J Schuuring; S M Boekholdt; A Windhausen; B J Bouma; M Groenink; M Keijzers; R J De Winter; D R Koolbergen; N A Blom; B J M Mulder
Journal:  Neth Heart J       Date:  2011-12       Impact factor: 2.380

5.  Recent progress in treatment of pulmonary arterial hypertension due to congenital heart disease.

Authors:  M J Schuuring; A C M J van Riel; B J Bouma; B J M Mulder
Journal:  Neth Heart J       Date:  2011-12       Impact factor: 2.380

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.